<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01215773</url>
  </required_header>
  <id_info>
    <org_study_id>1268.59</org_study_id>
    <secondary_id>2009-016369-27</secondary_id>
    <nct_id>NCT01215773</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers.</brief_title>
  <official_title>Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given 200 mg b.i.d. or 400 mg b.i.d. Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The main objectives of the multiple dose study are to investigate the safety, tolerability
      pharmacokinetics of BI 671800 HEA in healthy male and female volunteers following multiple
      oral administration of BI 671800
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vital signs (pulse rate (PR))</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory test (clinical chemistry)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory test (urinalysis)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs (blood pressure (BP))</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead ECG (electrocardiogram)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory test (haematology)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of tolerability by investigator</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum plasma concentration of BI 671800 or BI 600957)</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing until maximum concentration of BI 671800 or BI 600957 is measured)</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the plasma concentration-time curve of BI 671800 or BI 600957 from time of dosing extrapolated to infinity)</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ,1 (area under the plasma concentration-time curve of BI 671800 or BI 600957 for the complete dosing interval τ)</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the plasma concentration-time curve of BI 671800 or BI 600957 from time of dosing to time tz of last quantifiable concentration)</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss (maximum plasma concentration of BI 671800 or BI 600957 at steady state)</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,ss (time from dosing until maximum concentration of BI 671800 or BI 600957 at steady state is measured)</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cavg,ss (average measured plasma concentration of BI 671800 or BI 600957 at steady state)</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ,ss (area under the plasma concentration-time curve of BI 671800 or BI 600957 at steady state for the complete dosing interval τ)</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz,ss (terminal rate constant of BI 671800 or BI 600957 in plasma at steady state)</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,ss (terminal half-life of BI 671800 or BI 600957 in plasma at steady state)</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo,ss (mean residence time of BI 671800 in the body at steady state after oral administration)</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F,ss (apparent clearance of BI 671800 at steady state following oral administration)</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F,ss (apparent volume of distribution of BI 671800 during the terminal phase at steady state following oral administration)</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAUCτ,ss,M/P (ratio of AUCτ,ss of the BI 600957 to AUCτ,ss of BI 671800)</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RCmax,ss,M/P (ratio of Cmax,ss of the BI 600957 to Cmax,ss of BI 671800)</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>accumulation ratios RA,Cmax</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>accumulation ratios RA,AUC</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak-trough fluctuation (PTF) of BI 671800</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak-trough fluctuation (PTF) of BI 600957</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>linearity index (LI) of BI 671800 in plasma</measure>
    <time_frame>up to day 12 post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 671800 HEA medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet, oral administration with 240 mL of water for each treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 671800 HEA high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 Tablets, oral administration with 240 mL of water for each treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching to HEA 200 mg tablets, oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching to HEA 200 mg tablet, oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 671800</intervention_name>
    <description>High dose oral administration</description>
    <arm_group_label>BI 671800 HEA high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 671800</intervention_name>
    <description>Medium dose oral administration</description>
    <arm_group_label>BI 671800 HEA medium dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males and females according to the following criteria: Based upon a complete
             medical history, including physical examination, vital signs (Blood Pressure (BP),
             Pulse Rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests

          2. Age 21 to 50 years (incl.)

          3. Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl.)

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice (GCP) and the local legislation

        Exclusion criteria:

          1. Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance

          2. Any evidence of a clinically relevant concomitant disease

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          5. History of relevant orthostatic hypotension, fainting spells or blackouts

          6. Chronic or relevant acute infections

          7. History of relevant allergy or hypersensitivity (including allergy to drug or its
             excipients)

          8. Intake of drugs with a long half life (&gt;24 h) within one month or less than 10
             half-lives of the respective drug prior to first study drug administration

          9. Participation in another trial with an investigational drug within 2 months prior to
             administration or during the trial

         10. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes daily)

         11. Alcohol abuse (average consumption of more than 20 g/day in females and 30 g/day in
             males) or positive alcohol test

         12. Drug abuse

         13. Blood donation (more than 100 mL within four weeks prior to day 1 of visit 2)

         14. Any laboratory value outside the reference range that is of clinical relevance,
             especially repeated Alanine transaminase (ALT), Aspartate transaminase (AST),
             Gamma-glutamyl-transferase (GGT), Alkaline phosphatase (ALP) or total bilirubin above
             upper limit of normal (ULN) at screening and not resolved before dosing.

         15. Inability to comply with dietary regimen of trial site

         16. Use of drugs which might reasonably influence the results of the trial or that prolong
             the QT/QTc interval within 10 days prior to administration or during the trial, and
             CYP2C8 substrates such as amiodarone, amodiaquine, paclitaxel, rosiglitazone,
             pioglitazone and repaglinide or CYP2C9 such as warfarin, tolbutamide, phenytoin,
             losartan, acenocoumarol within 1 month or six half lives (whichever is greater).

         17. Repeated demonstration of a QTc interval &gt;450 ms, PR interval &gt;230 ms or a QRS
             interval &gt;120 ms; history of additional risk factors for torsade de pointes (e.g.,
             heart failure, hypokalaemia, family history of Long QT Syndrome)

             For female subjects of childbearing potential only:

         18. Positive pregnancy test, pregnancy or planning to become pregnant during the study or
             within 2 months after study completion

         19. No adequate contraception during the study including three months before first dosing
             until 2 month after study completion, e.g. not any of the following: implants,
             injectables, combined hormonal contraceptives, intrauterine device, or surgical
             sterilisation (including hysterectomy). In addition to this, also a barrier method
             (e.g. condom) will be required, if the female is not surgically sterilised.

         20. Lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1268.59.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ingelheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

